These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 10929879

  • 21. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium.
    Hill RL, Smith CT, Seyed-Akhavani M, Casewell MW.
    J Antimicrob Chemother; 1997 May; 39 Suppl A():23-8. PubMed ID: 9511058
    [Abstract] [Full Text] [Related]

  • 22. Medium and supplement effects on the antimicrobial activity of quinupristin/dalfopristin tested by agar dilution and Etest methods.
    Jones RN.
    Diagn Microbiol Infect Dis; 1996 Oct; 26(2):99-102. PubMed ID: 8985664
    [Abstract] [Full Text] [Related]

  • 23. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
    Nakashio S, Iwasawa H, Iino S, Shimada J.
    Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
    [Abstract] [Full Text] [Related]

  • 24. In-vitro activity of quinupristin/dalfopristin (Synercid) against isolates of Streptococcus pneumoniae, Staphylococcus aureus and enterococcus spp.
    Johnson AP, Warner M, Speller DC.
    J Antimicrob Chemother; 1997 Oct; 40(4):604-5. PubMed ID: 9372437
    [No Abstract] [Full Text] [Related]

  • 25. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
    Baudoux P, Lemaire S, Denis O, Tulkens PM, Van Bambeke F, Glupczynski Y.
    J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
    [Abstract] [Full Text] [Related]

  • 26. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.
    Williams JD, Maskell JP, Whiley AC, Sefton AM.
    J Antimicrob Chemother; 1997 May; 39 Suppl A():41-6. PubMed ID: 9511061
    [Abstract] [Full Text] [Related]

  • 27. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
    Sambatakou H, Giamarellos-Bourboulis EJ, Grecka P, Chryssouli Z, Giamarellou H.
    J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
    [Abstract] [Full Text] [Related]

  • 28. Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium.
    Winston DJ, Emmanouilides C, Kroeber A, Hindler J, Bruckner DA, Territo MC, Busuttil RW.
    Clin Infect Dis; 2000 May; 30(5):790-7. PubMed ID: 10817685
    [Abstract] [Full Text] [Related]

  • 29. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK.
    Drugs; 2002 May; 62(3):425-41. PubMed ID: 11827558
    [Abstract] [Full Text] [Related]

  • 30. Quinupristin/dalfopristin: a therapeutic review.
    Allington DR, Rivey MP.
    Clin Ther; 2001 Jan; 23(1):24-44. PubMed ID: 11219478
    [Abstract] [Full Text] [Related]

  • 31. Quinupristin-dalfopristin (RP 59500): an injectable streptogramin combination.
    Griswold MW, Lomaestro BM, Briceland LL.
    Am J Health Syst Pharm; 1996 Sep 01; 53(17):2045-53. PubMed ID: 8870891
    [Abstract] [Full Text] [Related]

  • 32. Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium.
    Lorian V, Fernandes F.
    J Antimicrob Chemother; 1997 May 01; 39 Suppl A():63-6. PubMed ID: 9511065
    [Abstract] [Full Text] [Related]

  • 33. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.
    Bouanchaud DH.
    J Antimicrob Chemother; 1997 May 01; 39 Suppl A():15-21. PubMed ID: 9511057
    [Abstract] [Full Text] [Related]

  • 34. Recent developments in streptogramin research.
    Barrière JC, Berthaud N, Beyer D, Dutka-Malen S, Paris JM, Desnottes JF.
    Curr Pharm Des; 1998 Apr 01; 4(2):155-80. PubMed ID: 10197038
    [Abstract] [Full Text] [Related]

  • 35. Effect of quinupristin/dalfopristin alone or in combination with vancomycin on the structure of Enterococcus faecium.
    Lorian V, Fernandes F.
    Drugs Exp Clin Res; 1998 Apr 01; 24(2):73-6. PubMed ID: 9675547
    [Abstract] [Full Text] [Related]

  • 36. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
    Lamb HM, Figgitt DP, Faulds D.
    Drugs; 1999 Dec 01; 58(6):1061-97. PubMed ID: 10651391
    [Abstract] [Full Text] [Related]

  • 37. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates.
    Schouten MA, Hoogkamp-Korstanje JA.
    J Antimicrob Chemother; 1997 Aug 01; 40(2):213-9. PubMed ID: 9301986
    [Abstract] [Full Text] [Related]

  • 38. Susceptibility to quinupristin/dalfopristin and other antibiotics of vancomycin-resistant enterococci from the UK, 1997 to mid-1999.
    Johnson AP, Warner M, Hallas G, Livermore DM.
    J Antimicrob Chemother; 2000 Jul 01; 46(1):125-8. PubMed ID: 10882701
    [Abstract] [Full Text] [Related]

  • 39. Methicillin-resistant, quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides.
    Werner G, Cuny C, Schmitz FJ, Witte W.
    J Clin Microbiol; 2001 Oct 01; 39(10):3586-90. PubMed ID: 11574577
    [Abstract] [Full Text] [Related]

  • 40. In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistant Streptococcus pneumoniae.
    Reinert RR, Kresken M, Mechery V, Lemperle M, Lütticken R.
    Eur J Clin Microbiol Infect Dis; 1998 Sep 01; 17(9):662-5. PubMed ID: 9832271
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.